Inflammatory bowel disease (IBD) typically manifests as either ulcerative colitis (UC) or Crohn's disease (CD). Systematic identification of susceptibility genes for IBD has thus far focused mainly on CD, and little is known about the genetic architecture of UC. Here we report a genome-wide association study with 440,794 SNPs genotyped in 1,167 individuals with UC and 777 healthy controls. Twenty of the most significantly associated SNPs were tested for replication in three independent European case-control panels comprising a total of 1,855 individuals with UC and 3,091 controls. Among the four consistently replicated markers, SNP rs3024505 immediately flanking the IL10 (interleukin 10) gene on chromosome 1q32.1 showed the most significant association in the combined verification samples (P = 1.35 × 10−12; OR = 1.46 (1.31–1.62)). The other markers were located in ARPC2 and in the HLA-BTNL2 region. Association between rs3024505 and CD (1,848 cases, 1,804 controls) was weak (P = 0.013; OR = 1.17 (1.01–1.34)). IL10 is an immunosuppressive cytokine that has long been proposed to influence IBD pathophysiology. Our findings strongly suggest that defective IL10 function is central to the pathogenesis of the UC subtype of IBD.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Loftus, E.V. Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126, 1504–1517 (2004).
Bouma, G. & Strober, W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3, 521–533 (2003).
Mathew, C.G. New links to the pathogenesis of Crohn disease provided by genome-wide association scans. Nat. Rev. Genet. 9, 9–14 (2008).
Duerr, R.H. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461–1463 (2006).
Franke, A. et al. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat. Genet. 40, 713–715 (2008).
Fisher, S.A. et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat. Genet. 40, 710–712 (2008).
Devlin, B. & Roeder, K. Genomic control for association studies. Biometrics 55, 997–1004 (1999).
Stokkers, P.C., Reitsma, P.H., Tytgat, G.N. & van Deventer, S.J. HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut 45, 395–401 (1999).
Marangoni, F. et al. WASP regulates suppressor activity of human and murine CD4(+)CD25(+)FOXP3(+) natural regulatory T cells. J. Exp. Med. 204, 369–380 (2007).
Webb, M.C., Andrews, P.A., Koffman, C.G. & Cameron, J.S. Renal transplantation in Wiskott-Aldrich syndrome. Transplantation 56, 1585 (1993).
van Heel, D.A. et al. Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs. Hum. Mol. Genet. 13, 763–770 (2004).
van der Linde, K. et al. A functional interleukin-10 mutation in Dutch patients with Crohn's disease. Dig. Liver Dis. 37, 330–335 (2005).
Balding, J. et al. Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphisms. Mediators Inflamm. 13, 181–187 (2004).
Parkes, M., Satsangi, J. & Jewell, D. Contribution of the IL-2 and IL-10 genes to inflammatory bowel disease (IBD) susceptibility. Clin. Exp. Immunol. 113, 28–32 (1998).
Tagore, A. et al. Interleukin-10 (IL-10) genotypes in inflammatory bowel disease. Tissue Antigens 54, 386–390 (1999).
Koss, K., Satsangi, J., Fanning, G.C., Welsh, K.I. & Jewell, D.P. Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies. Genes Immun. 1, 185–190 (2000).
Klein, W. et al. The IL-10 gene is not involved in the predisposition to inflammatory bowel disease. Electrophoresis 21, 3578–3582 (2000).
Aithal, G.P. et al. Role of polymorphisms in the interleukin-10 gene in determining disease susceptibility and phenotype in inflamatory bowel disease. Dig. Dis. Sci. 46, 1520–1525 (2001).
Kim, T.H. et al. Tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in Korean patients with inflammatory bowel disease. Korean J. Gastroenterol. 42, 377–386 (2003).
Celik, Y. et al. Cytokine gene polymorphisms in Turkish patients with inflammatory bowel disease. Scand. J. Gastroenterol. 41, 559–565 (2006).
Fernandez, L. et al. Interleukin-10 polymorphisms in Spanish patients with IBD. Inflamm. Bowel Dis. 11, 739–743 (2005).
Cantor, M.J., Nickerson, P. & Bernstein, C.N. The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease. Am. J. Gastroenterol. 100, 1134–1142 (2005).
Castro-Santos, P., Suarez, A., Lopez-Rivas, L., Mozo, L. & Gutierrez, C. TNFalpha and IL-10 gene polymorphisms in inflammatory bowel disease. Association of -1082 AA low producer IL-10 genotype with steroid dependency. Am. J. Gastroenterol. 101, 1039–1047 (2006).
Trikalinos, T.A., Ntzani, E.E., Contopoulos-Ioannidis, D.G. & Ioannidis, J.P. Establishment of genetic associations for complex diseases is independent of early study findings. Eur. J. Hum. Genet. 12, 762–769 (2004).
Kolbe, D. et al. Regulatory potential scores from genome-wide three-way alignments of human, mouse, and rat. Genome Res. 14, 700–707 (2004).
Hu, X., Chen, J., Wang, L. & Ivashkiv, L.B. Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation. J. Leukoc. Biol. 82, 237–243 (2007).
Mitsuyama, K. et al. Interleukin-10 in the pathophysiology of inflammatory bowel disease: increased serum concentrations during the recovery phase. Mediators Inflamm. 2006, 26875 (2006).
Schreiber, S., Heinig, T., Thiele, H.G. & Raedler, A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 108, 1434–1444 (1995).
Schreiber, S. et al. Ulcerative Colitis IL-10 Cooperative Study Grp TI Safety and tolerance of rHuIL-10 treatment in patients with mild/moderate active ulcerative colitis. Gastroenterology 114, A1080–A1081 (1998).
Steidler, L. et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289, 1352–1355 (2000).
We wish to thank all individuals with IBD, families and physicians for their cooperation. We gratefully acknowledge the cooperation of the German Crohn and Colitis Foundation (Deutsche Morbus Crohn und Colitis Vereinigung e.V.), the BMBF competence network “IBD” and of the contributing gastroenterologists. Finally, we wish to thank T. Wesse, T. Henke, A. Dietsch, R. Vogler, C.v.d. Lancken and M. Friskovec for expert technical help. We thank T. Wienker and M. Steffens (IMBIE, University of Bonn) for performing the quality control of the GWAS datasets. We thank B.A. Lie and the Norwegian Bone Marrow Donor Registry at Rikshospitalet University Hospital, Oslo, for contributing the healthy Norwegian control population. This study was supported by the German Ministry of Education and Research (BMBF) through the National Genome Research Network (NGFN), the popgen biobank and the SFB617 “Molecular Mechanisms of Epithelial Defense.” The project received infrastructure support through the DFG excellence cluster “Inflammation at Interfaces.” We acknowledge use of DNA from the 1958 British Birth Cohort collection (R. Jones, S. Ring, W. McArdle and M. Pembrey), funded by the UK MRC (grant G0000934) and The Wellcome Trust (grant 068545/Z/02). C.G.M. and C.M.O. were supported by The Wellcome Trust and CORE (UK).
A full list of members is provided in the Supplementary Note.
About this article
Cite this article
Franke, A., Balschun, T., Karlsen, T. et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 40, 1319–1323 (2008). https://doi.org/10.1038/ng.221
Genome Biology (2022)
Cancer cell-expressed BTNL2 facilitates tumour immune escape via engagement with IL-17A-producing γδ T cells
Nature Communications (2022)
Ulcerative colitis: understanding its cellular pathology could provide insights into novel therapies
Journal of Inflammation (2020)
Manipulating resident microbiota to enhance regulatory immune function to treat inflammatory bowel diseases
Journal of Gastroenterology (2020)
Species-specific enhancement of enterohemorrhagic E. coli pathogenesis mediated by microbiome metabolites